Home > Insider Trading > Filing (0000950142-13-001742)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
57055	Kv Pharmaceutical Co	KVPHQ	Pharmaceutical Preparations (2834)	430618919

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1138995	Glenview Capital Management, Llc	767 Fifth Avenue 44Th Floor New York NY 10153		No	No	Yes	No
1228603	M Lawrence Robbins	767 Fifth Avenue 44Th Floor New York NY 10153		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock, $0.01 Par Value	Acquisiton	2013-08-01	800,000	$0.58	5,958,983	No	4	P	Indirect	See footnotes
Class A Common Stock, $0.01 Par Value	Acquisiton	2013-08-02	703,000	$0.55	6,661,983	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Footnotes

These shares of the Issuer's Class A Common Stock, $0.01 par value per share (the "Shares") were purchased for the accounts of Glenview Capital Partners, L.P., Glenview Capital Master Fund, Ltd., Glenview Institutional Partners, L.P., Glenview Offshore Opportunity Master Fund, Ltd. and Glenview Capital Opportunity Fund, L.P.
Glenview Capital Management, LLC serves as investment manager to each of Glenview Capital Partners, L.P., Glenview Capital Master Fund, Ltd., Glenview Institutional Partners, L.P., Glenview Offshore Opportunity Master Fund, Ltd., and Glenview Capital Opportunity Fund, L.P. Mr. Robbins is the Chief Executive Officer of Glenview Capital Management, LLC. Each Reporting Person disclaims beneficial ownership of the Shares except to the extent of his or its pecuniary interest therein and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the Shares for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.
This price reflects the weighted average purchase price for open-market purchases of Shares made by the Reporting Persons on August 2, 2013 within a $1.00 range. The actual prices for these transactions range from $0.5285 to $0.5899, inclusive. The Reporting Persons further undertake to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.